

# **BG Indexes 12-month performance** SOFIX 530 500 470 440 410 380 22.09.2020 22.01.202 22.02.202 22.03. **BGBX 40** 125 22.01.2021 22.05.2021 22.03.2021 22.04.2021

Index	Close	Weekly Chg.%	YTD
SOFIX	551.89	1.73	23.32
BGBX 40	122.98	1.86	21.31
BGREIT	153.48	0.39	11.47
la dess	D/E	EVIC	D/DV

Index	P/E	EV/S	P/BV
SOFIX	21.05	0.33	0.58
BGBX 40	21.90	0.66	0.75
BGREIT	13.47	n/a	0.81

BSE weekly gainers & losers							
Top Gainers		Price	Chng %				
DUH	Doverie Holding AD	5.90	13.90				
MSH	M+S Hidravlik AD	7.60	5.56				
MONB	Monbat AD	6.00	4.35				
SPH	Stara Planina Hold AD	7.30	4.29				
Top Losers		Price	Chng %				
SFT	Sopharma Trading AD	5.15	-0.96				
T57	Trace Group Hold AD	3.80	-1.04				
NEOH	Neochim AD	25.80	-1.53				
TBS	Telelink Business Services	13.60	-3.55				

# Market Overview (June 14th - June 18th)

The main Bulgarian index **SOFIX** increased by 1.73% this week, up to 551.89 points. The broad index **BGBX40** increased by 1.86% to 122.98 points. **BGREIT** increased this trading week to 153.48 points, up by 0.39%.

## **Corporate News**

**Fazerles AD (FZLS)** announced a dividend for 2020 in the amount of BGN 1.00 per share distributing total of BGN 5.4mln to shareholders.

**Lavena AD (LAV)** announced a dividend for 2020 in the amount of BGN 0.03 per share distributing total of BGN 0.3mln to shareholders.

**Industrialen Capital Holding AD (HIKA)** announced a dividend for 2020 of BGN 0.07368421 per share distributing total of BGN 1.2mln to shareholders.

**Fairplay Properties (FPP)** announced increase of the capital through warrants. Total amount which warrant holders can subscribe to is over BGN 232mln though 232 017 800 shares of BGN 1 each.

#### **Economic News**

Bulgaria's consumer prices went up by 2.5% from a year earlier in May 2021, following a 2% increase in the previous month.

Bulgaria's trade deficit widened to BGN 288.3 mln in April 2021 from BGN 72.6 million in the corresponding month of the previous year. Exports surged 47.9% yoy and imports soared 52.5% yoy, both due to baseline effect from covid19.

The Current Account surplus narrowed to EUR 7.8mil in April 2021 from EUR 24.2mil surplus the year before. In the first 4 months of 2021 the CA balance switched to EUR 103mil deficit compared to EUR 315mil surplus for the same period the previous year.

Active COVID-19 cases in Bulgaria are on a firmly decreasing trend with a 7-day MA of 110 cases. The incidence of coronavirus in the country is at bottom figures of ca. 100 infections per day. The total number of fully vaccinated people so far is 735 898, which is 10.7% of the population in Bulgaria.

This document is published solely for informational purposes and is based on sources believed to be reliable.



### Disclaimer

#### Guarantees

The analyst (s) responsible for the preparation of this document shall ensure that: (1) they take all necessary care to accurately reflect the information contained in this document; (2) no part of the analyst's remuneration is, has been or will be linked, directly or indirectly, to the recommendation or opinions expressed in this document.

**Financial interest**: Sofia International Securities may trade or own the financial instruments specified in this document. Sofia International Securities does not own more than 5% of the financial instruments in circulation, subject to analysis or comment in this document. The analyst (s) do not own any shares of the companies, unless explicitly mentioned.

# Disclosure of information

Due care has been taken to ensure the accuracy of the facts cited, the reliability of the sources of information and the clear definition of the assumptions, predictions, forecasts and expected prices in this document. The information presented in this document is based on publicly available information, which is considered reliable, but for which no responsibility is taken for completeness and accuracy. Neither Sofia International Securities nor the company's employees should be held responsible for the publicly available information used. The opinion expressed in this document may differ from the disclosed views in other departments and divisions of Sofia International Securities or from other employees. Additional information on this document is available upon request. The sources of information in the tables and graphs in this document are calculations by Sofia International Securities, unless otherwise stated.

### Risks for investors

This document has been prepared and presented for the purpose of summary and informational purposes only and does not constitute a study within the meaning of Art. 13 of Commission Delegated Directive (EU) 2017/593 of 7 April 2016. The information in this document should not be considered as an offer to buy or sell financial instruments or an independent investment council within the meaning of Directive 2014/65 / EU of The European Parliament and the Council of 15 May 2014, Sofia International Securities AD has not assessed the appropriateness in relation to the financial instruments mentioned in this document. The investment opportunities discussed in this document may not be appropriate for certain investors depending on their investment objectives and time horizon or in the context of their overall financial condition. The risks associated with investing in the financial instruments mentioned in this document are not fully explained. The price or value of the investment may decrease or increase. Securities or investments can lead to losses for the investor. A previous achievement is not a guarantee of future performance. Changes in exchange rates may have an adverse effect on the value, price or return on investment in securities. Sofia International Securities AD assumes no responsibility for losses incurred in connection with investments made on the basis of information contained in this document.

#### Copyright

The analyzes of Sofia International Securities are the exclusive property of the investment intermediary and any publication, distribution, reprinting and citation of content is possible only after the explicit written consent of the "Research and Analysis" department of the company. It is not allowed to use the analyzes of the investment intermediary from a third party for commercial purposes.